Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II valganciclovir in infants and children with congenital cytomegalovirus and hearing loss
2014-001920-31Phase 2Completed
- Sponsor
- University College London
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of valganciclovir in congenital cytomegalovirus infection (cCMV) and sensorineural hearing loss (SNHL) (2 arms), sponsored by University College London. Primary endpoint: Change in total ear hearing assessments. Started Apr 2015; status: completed.
02
Drugs
valganciclovir
03
Conditions
congenital cytomegalovirus infection (cCMV)sensorineural hearing loss (SNHL)
Beyond the preview
Go deeper on 2014-001920-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001920-31.